Feedback
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
We would very much appreciate any thoughts you may have about OpenCME and how it could be made more useful for physicians like you.
Beth Israel Deaconess Medical Center
Dana-Farber Harvard Cancer Center Kidney Cancer Program
Harvard Medical School
Boston, Massachusetts
University of Chicago
Chicago, Illinois
City of Hope
Duarte, California
Credit Types: | CME |
Credit Amount: | 1.5 Credits |
Release Date: | 2018-Mar-22 |
Expiration Date: | 2019-Mar-21 |
Estimated Time for Completion: | 90 minutes |
Registration Required: | No |
Cost: | Free of Charge |
In this activity, renal cell carcinoma (RCC) experts discuss perspectives on recent clinical trends and guide adoption of a more nuanced and personalized approach to selecting and sequencing the available treatment options through the advanced RCC continuum. Illustrative cases detail therapeutic decision points based on patient and disease characteristics and are paired with analysis of the latest evidence on disease management and application of key clinical concepts to practice.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of medical and urologic oncologists and other clinicians involved in the management of patients with RCC.
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Enduring Material
Release and Expiration Dates: March 22, 2018 - March 21, 2019
Time to Complete: 90 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.
David F. McDermott, MD
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Dana-Farber Harvard Cancer Center Kidney Cancer Program
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
David F. McDermott, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Array BioPharma.; Bristol-Myers Squibb Company; Eisai Inc.; Exelixis, Inc.; Genentech, Inc.; Merck Sharp & Dohme Corp.; Novartis Pharmaceuticals Corporation; and Pfizer Inc.
Grant/Research Support from Prometheus Laboratories.
David F. McDermott, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.
Walter M. Stadler, MD, FACP
Fred C. Buffett Professor of Medicine & Surgery
Chief, Section Hematology/Oncology
Department of Medicine
University of Chicago
Chicago, Illinois
Walter M. Stadler, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb Company; CVS Caremark; Genentech, Inc.; and Pfizer Inc.
Other Financial or Material Support: Data Safety Monitoring Board for AstraZeneca; Bayer Corporation; Eisai Inc.; and Sotio, LLC. Editorial activities for American Cancer Society and UpToDate Inc.
Walter M. Stadler, MD, FACP, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.
Sumanta Kumar Pal, MD
Associate Clinical Professor, Genitourinary Malignancies
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of Hope
Duarte, California
Sumanta Kumar Pal, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bayer Corporation; Bristol-Myers Squibb; and Genentech, Inc.
Advisory Board for AstraZeneca; Bayer Corporation; Bristol-Myers Squibb; CytomX Therapeutics, Inc.; Eisai Inc.; Exelixis, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Novartis Pharmaceuticals Corporation.
Sumanta Kumar Pal, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: Various combination strategies with targeted agents and immunotherapies for renal cell carcinoma.
Amer Assal, MD
Columbia University Medical Center
Blood and Marrow Transplantation Program
New York, New York
Amer Assal, MD, has no financial interests/relationships or affiliations in relation to this activity.
Aarati Ranganathan, PhD
PVI, PeerView Institute for Medical Education
Aarati Ranganathan, PhD, has no financial interests/relationships or affiliations in relation to this activity.
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This educational activity is supported by a medical education grant from Exelixis, Inc.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.
Copyright © 2000-2018, PeerView
"OpenCME has initially been made available in a "beta" edition with minimal content, functionality and online presence. Our editorial team is working hard to add many other specialty areas to the list above."
Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.
Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.